TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9029752

Group type: EXPERIMENTAL
Intervention: 1-g oral dose of vigabatrin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 2-g and 4-g oral doses of vigabatrin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.75-g dose of vigabatrin in renal failure patients
Number of subjects: 59
Study: 8498730

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg/pseudoephedrine hydrochloride 120 mg (T/Ps)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: clemastine fumarate 1.34 mg/phenylpropanolamine 75 mg (C/Ph)
Number of subjects: 178
Study: 3278574

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine (group 1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nifedipine (group 1)
Number of subjects: 149
Study: 31957334

Group type: EXPERIMENTAL
Intervention: TDM-guided dosing
Number of subjects: 70

Group type: COMPARATOR
Intervention: Current practice (160 mg/m2)
Number of subjects: 70
Study: 31455386

Group type: COMPARATOR
Intervention: Propofol at 0 μg.ml ‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol at 0.5 μg.ml ‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol at 1.0 μg.ml ‐1
Number of subjects: 30
Study: 27496969

Group type: EXPERIMENTAL
Intervention: DNA hypermethylation analysis of biomarkers RASSF1A, 3OST2, PRDM14
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: RASSF1A
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sputum cytology
Number of subjects: 284
Study: 26028494

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 23459398

Group type: EXPERIMENTAL
Intervention: 4PCP training program (active learning arm and clinical support arm)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4PCP training program
Number of subjects: 31
Study: 21688873

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Educational Feedback Control (EFC)
Number of subjects: 205
Study: 18463125

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT
Number of subjects: 476

Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 476
Study: 21355149

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion combined with Alendronate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Alendronate only
Number of subjects: 55
Study: 16108508

Group type: EXPERIMENTAL
Intervention: Topical anti-histamine/decongestant eye drops
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conservative management (washing eyes with cold water and applying ice packs)
Number of subjects: 200
Study: 12126869

Group type: EXPERIMENTAL
Intervention: Amisulpride (400‐800 mg/day, n = 339)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Haloperidol (15‐20 mg/day, n = 160)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Risperidone (8 mg/day, n = 113)
Number of subjects: 612
Study: 9641175

Group type: EXPERIMENTAL
Intervention: AN140
Number of subjects: 16
Study: 7806817

Group type: EXPERIMENTAL
Intervention: Continuous splinting (early treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous splinting (delayed treatment)
Number of subjects: 40
Study: 2699608

Group type: EXPERIMENTAL
Intervention: Tranylcypromine (5 mg once a day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 766567

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30769272

Group type: EXPERIMENTAL
Intervention: Pitavastatin with/without eicosapentaenoic acid
Number of subjects: 140
Study: 30579342

Group type: COMPARATOR
Intervention: Tetracaine mucilage instilled into the urethra and applied to the catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracaine mucilage in combination with image illustration on CRBD
Number of subjects: 60
Study: 27098676

Group type: EXPERIMENTAL
Intervention: Targeted invitation materials
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control invitation materials
Number of subjects: 2000
Study: 25415158

Group type: EXPERIMENTAL
Intervention: DHA supplementation (450 mg per day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22776103

Group type: EXPERIMENTAL
Intervention: 20-session home-based therapeutic intervention program (18 one-hour sessions in three 6-week blocks) targeting language development domains.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20-session home-based therapeutic intervention program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 200
Study: 19036079

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG (ara‐C = 7590 mg/m2)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐DCTER (ara‐C = 800 mg/m2)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara‐C) therapy
Number of subjects: 457
Study: 17935765

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate combination (SFC)
Number of subjects: 3416

Group type: COMPARATOR
Intervention: fluticasone propionate (FP)
Number of subjects: 3416
Study: 15300807

Group type: EXPERIMENTAL
Intervention: Serum PSA < 3 ng/ml
Number of subjects: 80458

Group type: EXPERIMENTAL
Intervention: Serum PSA 3.0-3.9 ng/ml with benign digital rectal examination or free total PSA ratio > or = 0.16
Number of subjects: 80458
Study: 11253317

Group type: EXPERIMENTAL
Intervention: Blocked practice with simple relative timing patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked practice with complex relative timing patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study: 9638987

Group type: EXPERIMENTAL
Intervention: PCR analysis of fine needle aspiration (FNA) samples
Number of subjects: 49

Group type: COMPARATOR
Intervention: FNA morphological examination
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PCR analysis when samples were inadequate for cytologic examination
Number of subjects: 49
Study: 8208391

Group type: EXPERIMENTAL
Intervention: Phentolamine (35 mg) after saline infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylephrine (500 micrograms) after saline infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 2592580

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 8 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg every 12 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (every 12 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 12
Study: 4827383

Group type: EXPERIMENTAL
Intervention: TCu 200
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCu 300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCu 380A
Number of subjects: 0
Study: 30048414

Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard erythemal dose in T‐shirt and shorts, three times per week for 4 wk and then once per week for 8 wk)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU·d for 4 wk and then 400 IU·d for 8 wk)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 28853117

Group type: EXPERIMENTAL
Intervention: Neurostimulation (NS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 21
Study: 26190666

Group type: EXPERIMENTAL
Intervention: Informed physiotherapy with monitoring device during pendulum exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uninformed home rehabilitation
Number of subjects: 24
Study: 23177758

Group type: EXPERIMENTAL
Intervention: Single-jaw procedure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Double-jaw procedure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 24
Study: 21094321

Group type: EXPERIMENTAL
Intervention: Motorcycle simulator training
Number of subjects: 410

Group type: COMPARATOR
Intervention: Passive training based on a road safety lesson
Number of subjects: 410
Study: 18683001

Group type: EXPERIMENTAL
Intervention: SDA-SBO (24 ml/day providing approximately 3.7 g SDA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EPA (approximately 1 g/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular SBO (control group)
Number of subjects: 45
Study: 17062681

Group type: EXPERIMENTAL
Intervention: Rituximab and IL‐12 (arm A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Rituximab followed by IL‐12 after progression (arm B)
Number of subjects: 58
Study: 12452400

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hyoscine butyl-bromide
Number of subjects: 53
Study: 10508799

Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: MDI with holding chamber
Number of subjects: 10
Study: 7554393

Group type: EXPERIMENTAL
Intervention: IL-6 administered by daily subcutaneous injection for 7 days at a dose level of 1, 3, or 10 micrograms/kg/day
Number of subjects: 8
Study: 2254511

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting-list control (WL) after treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CB) at 10-week follow-up
Number of subjects: 44
Study: 7437255

Group type: EXPERIMENTAL
Intervention: Oxyfedrine (maximum dose 32 mg three times daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (maximum dose 120 mg three times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30058174

Group type: EXPERIMENTAL
Intervention: Atrioventricular optimization algorithm (SmartDelay™)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Fixed AV Delay of 120 ms with biventricular pacing
Number of subjects: 726
Study: 28464364

Group type: EXPERIMENTAL
Intervention: MMR and web‐based intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: MMR
Number of subjects: 99
Study: 26278037

Group type: EXPERIMENTAL
Intervention: POD 3 drain removal
Number of subjects: 106

Group type: COMPARATOR
Intervention: POD 5 drain removal
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: POD 1 drain and serum amylase values
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Moderate/high risk patients
Number of subjects: 106
Study: 23030836

Group type: EXPERIMENTAL
Intervention: Interactive video gaming (IVG) using Nintendo Wii Fit for 3 weeks
Number of subjects: 14
Study: 21088453

Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Safflowerseed oil supplementation
Number of subjects: 13
Study: 18323317

Group type: EXPERIMENTAL
Intervention: Computer-assisted decision making (CADM) using a handheld device
Number of subjects: 4

Group type: COMPARATOR
Intervention: No CADM technology (control)
Number of subjects: 4
Study: 17158441

Group type: EXPERIMENTAL
Intervention: Policosanol (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14623840

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Bi-level Positive Airway Pressure (BiPAP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for APO subgroup
Number of subjects: 101

Group type: COMPARATOR
Intervention: Bi-level Positive Airway Pressure (BiPAP) for APO subgroup
Number of subjects: 101
Study: 10945421

Group type: EXPERIMENTAL
Intervention: Shoulder strapping for six weeks in addition to standard physiotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: No strapping (control group)
Number of subjects: 98
Study: 9234881

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Idiopathic osteonecrosis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control subjects (healthy donors)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control subjects (bone-marrow grafting for non-union)
Number of subjects: 41
Study: 8134738

Group type: EXPERIMENTAL
Intervention: Cox model analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification and Regression Tree (CART) technique
Number of subjects: 0
Study: 2824365

Group type: EXPERIMENTAL
Intervention: Short-term dietary sodium restriction in normotensive adolescents
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Long-term dietary intervention in hypertensive adults
Number of subjects: 508

Group type: COMPARATOR
Intervention: Lithium countertransport in hypertensive adults treated with antihypertensive medications
Number of subjects: 508

Group type: COMPARATOR
Intervention: Lithium countertransport in normotensive adults
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Sodium-stimulated lithium countertransport
Number of subjects: 508
Study: 31036563

Group type: EXPERIMENTAL
Intervention: EX+BR (exercise + breaks): sitting (1 hour), moderate-intensity walking (30 min), sitting interrupted every 30 min with 3 min of light-intensity walking (6.5 hours)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: EX+SIT (exercise + sitting): sitting (1 hour), moderate-intensity walking (30 min), uninterrupted sitting (6.5 hours)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: EX+SIT (exercise + sitting)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: EX+BR (exercise + breaks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: SIT (sitting): uninterrupted sitting (8 hours, control)
Number of subjects: 67
Study: 29884603

Group type: EXPERIMENTAL
Intervention: Healthy Mom Zone Intervention (adaptive intervention with step-ups in dosages)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 31
Study: 26507862

Group type: EXPERIMENTAL
Intervention: 3.5 mg of rhBMP‐7 (Osigraft OP1) on a type I collagen carrier
Number of subjects: 11
Study: 25479219

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic medial maxillectomy (for recurrent cases)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic medial maxillectomy (for primary cases)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Transnasal endoscopic resection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Caldwell-Luc operation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Redo transnasal endoscopic medial maxillectomy (Caldwell-Luc group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Other groups (not specified)
Number of subjects: 51
Study: 22933541

Group type: EXPERIMENTAL
Intervention: Vitamin D3 10 μg/d
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Vitamin D3 30 μg/d
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Vitamin D3 40 μg/d
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (10 μg/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (30 μg/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (40 μg/d)
Number of subjects: 113
Study: 20816189

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 318

Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP)
Number of subjects: 318
Study: 18453796

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 9739

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 9739

Group type: EXPERIMENTAL
Intervention: SBP < 140 mm Hg
Number of subjects: 9739

Group type: EXPERIMENTAL
Intervention: Lowest LDL-C tertile with SBP < 140 mm Hg
Number of subjects: 9739

Group type: EXPERIMENTAL
Intervention: Lowest LDL-C tertile
Number of subjects: 9739
Study: 15722809

Group type: EXPERIMENTAL
Intervention: Pain intensity (100 mm Visual Analog Scale [VAS])
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Pain frequency
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Daily pain duration
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Pain behavior (verbal 6-point scale)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Pain patterns
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Medication use
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Daily mean VAS scores
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Maximal VAS score
Number of subjects: 133
Study: 11973381

Group type: EXPERIMENTAL
Intervention: Composite solution I (amphipathic lipids)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Composite solution II (amphipathic lipids)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (contralateral eye treated with no intervention)
Number of subjects: 20
Study: 9433341

Group type: EXPERIMENTAL
Intervention: Repeated dextroamphetamine challenge
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8133112

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescent antibody (IFA) test for detection of Babesia microti antibody
Number of subjects: 130
Study: 2804996

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 797057

Group type: EXPERIMENTAL
Intervention: Premedication
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Psychic conditioning
Number of subjects: 110

Group type: COMPARATOR
Intervention: Dental procedures (extraction, filling therapy, prosthodontic procedures)
Number of subjects: 110
Study: 7315832

Group type: EXPERIMENTAL
Intervention: Sphygmetrics SR-2 Automatic Blood Pressure Recorder
Number of subjects: 71

Group type: COMPARATOR
Intervention: Auscultation using a biaural stethoscope and mercury sphygmomanometer
Number of subjects: 71
Study: 31992394

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30657023

Group type: EXPERIMENTAL
Intervention: Vaginal ring delivering the antiretroviral dapivirine
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Participant engagement activities
Number of subjects: 214
Study: 28445659

Group type: EXPERIMENTAL
Intervention: Adalimumab (20 mg or 40 mg according to body weight, administered subcutaneously every 2 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (administered subcutaneously every 2 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25537159

Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg/week)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 29
Study: 24345071

Group type: EXPERIMENTAL
Intervention: Outdoor activities ≤9.0 hours/week
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Outdoor activities >9.0 hours/week
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Nearwork activity >21.0 hours/week
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Nearwork activity ≤21.0 hours/week
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Baseline nearwork as a continuous variable
Number of subjects: 469
Study: 21776572

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 113
Study: 19556536

Group type: EXPERIMENTAL
Intervention: 375 U/kg of recombinant human erythropoietin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 750 U/kg of recombinant human erythropoietin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1500 U/kg of recombinant human erythropoietin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erythropoietin at any dose
Number of subjects: 32
Study: 17492951

Group type: EXPERIMENTAL
Intervention: Intravenous FFA infusion (intralipid/heparin infusion 4 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH administration (0.5 mg i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHR blockade (pegvisomant, 30 mg s.c.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 8
Study: 15352967

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of Propacetamol (2 g) and Diclofenac (75 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study: 12029287

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.75% ropivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1% ropivacaine
Number of subjects: 24
Study: 9828851

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 micrograms/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 1500 micrograms/day
Number of subjects: 30
Study: 7859697

Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 1
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 2
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 3
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: FFQ completed after 4-6 weeks
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: FFQ completed after 3 months
Number of subjects: 651